Cost-Effectiveness Analysis of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Adults 60 Years of Age and Older in Japan
Author(s)
Yoko Hirano, PhD1, Kosaku Komiya, MD,PhD2, Kazumasa Kamei, PhD1, Asuka Yoshida, PhD3, Junko Morii, BS,MPH4, Ryohei Kobayashi, MSc4, Reiko Sato, PhD5;
1Pfizer Japan Inc., Japan Access & Value, Tokyo, Japan, 2Oita University Faculty of Medicine, Respiratory Medicine and Infectious Diseases, Yufu-shi, Oita, Japan, 3Pfizer Japan Inc., Japan Vaccine Medical Affairs, Tokyo, Japan, 4IQVIA Solutions Japan G.K., Real World Evidence Solutions, Tokyo, Japan, 5Pfizer Inc., Global Access and Value, Pennsylvania, PA, USA
1Pfizer Japan Inc., Japan Access & Value, Tokyo, Japan, 2Oita University Faculty of Medicine, Respiratory Medicine and Infectious Diseases, Yufu-shi, Oita, Japan, 3Pfizer Japan Inc., Japan Vaccine Medical Affairs, Tokyo, Japan, 4IQVIA Solutions Japan G.K., Real World Evidence Solutions, Tokyo, Japan, 5Pfizer Inc., Global Access and Value, Pennsylvania, PA, USA
Presentation Documents
OBJECTIVES: Respiratory syncytial virus (RSV) is one of the leading pathogen that causes serious acute respiratory illnesses in older adults. In 2024, a bivalent RSV prefusion F protein-based (RSVpreF) vaccine for adults ≥60 years old was approved in Japan. As of December 2024, RSV vaccines are not included in the routine national immunization program. This study evaluated the cost-effectiveness of RSVpreF vaccine for adults ≥60 years old in Japan.
METHODS: A cohort model with Markov-type process was adapted to estimate lifetime risk of health and economic outcomes from both a payer’s and a societal perspective. Model inputs were estimated using data from Japan-specific published sources, with data from other countries, as needed. RSVpreF was assumed protective for 4 seasons, with some waning; effectiveness was derived from Phase III trial ("RENOIR") data. Model outcomes included the number of medically-attended RSV cases, stratified by care setting (i.e., hospitalizations, emergency department visits, outpatient visits), and attributable RSV-related deaths, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) of RSVpreF vaccination compared with no vaccination.
RESULTS: RSVpreF vaccination could prevent 860,104 medically attended RSV cases (hospitalizations: 204,145; emergency department visits: 113,170; outpatient visits: 542,790) and 27,764 deaths. The ICERs were under Japanese yen (JPY) 5 million/QALY (the threshold value in Japan) gained from both payer’s and societal perspectives. The ICERs were also under JPY 5 million/QALY when the target age populations were restricted (≥65, ≥70, ≥75, ≥80, ≥85, ≥90, and ≥95 years old). A series of sensitivity analyses confirmed the robustness of the base case results.
CONCLUSIONS: RSVpreF vaccination was a cost-effective strategy for the prevention of RSV disease in Japanese adults 60 years of age and older. The introduction of RSV vaccination has the potential to improve public health by reducing RSV cases and saving lives in Japan.
METHODS: A cohort model with Markov-type process was adapted to estimate lifetime risk of health and economic outcomes from both a payer’s and a societal perspective. Model inputs were estimated using data from Japan-specific published sources, with data from other countries, as needed. RSVpreF was assumed protective for 4 seasons, with some waning; effectiveness was derived from Phase III trial ("RENOIR") data. Model outcomes included the number of medically-attended RSV cases, stratified by care setting (i.e., hospitalizations, emergency department visits, outpatient visits), and attributable RSV-related deaths, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) of RSVpreF vaccination compared with no vaccination.
RESULTS: RSVpreF vaccination could prevent 860,104 medically attended RSV cases (hospitalizations: 204,145; emergency department visits: 113,170; outpatient visits: 542,790) and 27,764 deaths. The ICERs were under Japanese yen (JPY) 5 million/QALY (the threshold value in Japan) gained from both payer’s and societal perspectives. The ICERs were also under JPY 5 million/QALY when the target age populations were restricted (≥65, ≥70, ≥75, ≥80, ≥85, ≥90, and ≥95 years old). A series of sensitivity analyses confirmed the robustness of the base case results.
CONCLUSIONS: RSVpreF vaccination was a cost-effective strategy for the prevention of RSV disease in Japanese adults 60 years of age and older. The introduction of RSV vaccination has the potential to improve public health by reducing RSV cases and saving lives in Japan.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE419
Topic
Economic Evaluation
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Vaccines